Thus, a Bi-FAP/mEnd-IL formulation tailored for the targeting of human endoglin and FAP will be suitable for the targeted delivery of drugs and contrast agents into human neoplastic cells, and the tumor microenvironment components including the TAFs, tumor vasculature and also TAMs. The gene discussed is ENG; the disease is neoplasm.